Payment overview · 2025
General Payments
$1,416.23
90 reported records · 19 companies
Healthcare provider profile · identity verified
Jami T Perry, MD
Allopathic & Osteopathic Physicians|Family Medicine · PROVIDENCE, KY · NPI 1710050729
Verified facts
What the public records show
CMS Open Payments records show Jami T Perry, MD received $1,416.23 in general payments during 2025 across 90 reported records.
ABBVIE INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $358.78 | 25.3% | 28 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $180.48 | 12.7% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $171.76 | 12.1% | 9 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $157.58 | 11.1% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $87.57 | 6.2% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.68 | 4.6% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $61.24 | 4.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.29 | 4.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.03 | 3.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.06 | 3.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.83 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.68 | 2.1% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.87 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.62 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.66 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.44 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.94 | 1.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.88 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,416.23 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $225.15 | 12 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $180.48 | 8 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $157.58 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $156.69 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $134.02 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.63 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $75.64 | 8 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $61.24 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $58.56 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.03 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $37.74 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $37.74 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| I-STAT Normalized: i stat |
Device | Abbott Laboratories | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $11.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 118 |
| Losartan Potassium | Losartan Potassium | 430 | 98 |
| Lisinopril | Lisinopril | 420 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 67 |
| Furosemide | Furosemide | 248 | 62 |
| Trazodone Hcl | Trazodone Hcl | 248 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 59 |
| Metformin Hcl | Metformin Hcl | 216 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 54 |
| Gabapentin | Gabapentin | 209 | 39 |
| Omeprazole | Omeprazole | 193 | 50 |
| Sertraline Hcl | Sertraline Hcl | 184 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 34 |
| Simvastatin | Simvastatin | 141 | 36 |
| Ozempic | Semaglutide | 140 | 22 |
| Montelukast Sodium | Montelukast Sodium | 138 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 21 |
| Famotidine | Famotidine | 116 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 29 |
| Potassium Chloride | Potassium Chloride | 99 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 26 |
| Ondansetron Odt | Ondansetron | 93 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 38 |
| Januvia | Sitagliptin Phosphate | 82 | 14 |
| Allopurinol | Allopurinol | 81 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 13 |
| Glipizide | Glipizide | 81 | 17 |
| Prednisone | Prednisone | 81 | 60 |
| Meloxicam | Meloxicam | 80 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 20 |
| Atenolol | Atenolol | 72 | 18 |
| Lorazepam | Lorazepam | 72 | 15 |
| Alendronate Sodium | Alendronate Sodium | 71 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 18 |
| Azithromycin | Azithromycin | 65 | 61 |
| Pregabalin | Pregabalin | 64 | 11 |
| Carvedilol | Carvedilol | 63 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 18 |
| Clonidine Hcl | Clonidine Hcl | 60 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 16 |
| Buspirone Hcl | Buspirone Hcl | 56 | 18 |
| Metformin Hcl Er | Metformin Hcl | 56 | 14 |
| Eliquis | Apixaban | 54 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Nystatin | Nystatin | 49 | 29 |
| Meclizine Hcl | Meclizine Hcl | 48 | 16 |
| Diazepam | Diazepam | 46 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Indapamide | Indapamide | 44 | suppressed |
| Sucralfate | Sucralfate | 44 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 12 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Propranolol Hcl | Propranolol Hcl | 42 | 12 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Glimepiride | Glimepiride | 37 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 28 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 12 |
| Fluconazole | Fluconazole | 35 | 23 |
| Tramadol Hcl | Tramadol Hcl | 35 | 14 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 14 |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 13 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | 12 |
| Naproxen | Naproxen | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,416.23 · 90 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ABRYSVO, AIRSUPRA, Auvelity, Azstarys, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, ETERNA, FANAPT, GARDASIL 9, HETLIOZ, I-STAT, Jornay PM, LYBALVI, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Senza, Symbravo, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error